FINHUB Insights

IDXX · Q2 FY25 · Apr 1 – Jun 30, 2025

Idexx Laboratories Q2 FY25: where the revenue came from and where it went

Idexx Laboratories Q2 FY25: revenue $1.1B (+11% year over year). Net profit $0.3B. Largest cohort IDEXX VetLab consumables $0.4B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2025
Reported
Aug 4, 2025 10-Q
Sankey diagram of Idexx Laboratories's income statement for Q2 FY25: revenue of $1.1 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$1.1B +11% year over year
Gross profit$0.7B 63% margin
Operating profit$0.4B 34% margin
Net profit$0.3B 26% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
ItemValueShare of revenueYear over year
Revenue 1.1 100% +11%
IDEXX VetLab consumables 0.4 36% +15%
Reference laboratory diagnostic… 0.4 36% +6%
Rapid assay products 0.1 9% −3%
Recurring revenue 0.1 9% +9%
CAG Diagnostics capital… 0.1 9% +66%
Water segment revenue 0.1 9%
Cost of revenue−0.436%
Gross profit0.763% margin+1pp
Research & development−0.16%+0pp
Sales & marketing−0.115%+0pp
G&A−0.19%−7pp
Operating profit0.434% margin+7pp
Tax−0.1
Net profit0.326%+6pp
Filing on EDGAR More quarters of IDXX

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters